Marras T K, Chan C K, Lipton J H, Messner H A, Szalai J P, Laupacis A
Joint Division of Respirology, Department of Medicine, University Health Network and Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
Bone Marrow Transplant. 2004 Mar;33(5):509-17. doi: 10.1038/sj.bmt.1704377.
We studied long-term pulmonary function testing (PFT) in a retrospective cohort of 6-month survivors of allogeneic marrow transplant (BMT) between 1980 and 1997. Of 593 patients, 73, 71 and 65% had adequate data to assess for obstruction, restriction and diffusion impairments respectively. Over 5 years, mean declines in 1-s forced expiratory volume/forced vital capacity (FEV1/FVC), total lung capacity (TLC) and diffusion were 4, 7 and 17%, respectively. TLC and diffusion tended to subsequently increase. In all, 6, 12 and 35% of patients met criteria for obstruction, restriction and impaired diffusion, respectively. Obstruction was less common in recent transplants (5 vs 15%, P=0.004), while restriction and diffusion impairment rates remained stable. There was significantly greater mortality with obstruction (HR 2.0 (1.04-3.95)), and a nonstatistically significant higher mortality rate with restriction (HR 1.6 (0.95-2.75)), but not with impaired diffusion (HR=0.99 (0.65-1.50)). cGVHD (OR 16.7 (2.2-129.8)) and busulfan (OR 2.9 (1.01-8.24)) were associated with obstruction. Marrow from nonsibling or mismatched donors (OR 4.9 (2.2-10.7)) was associated with restriction. In summary, after BMT, decreased diffusion capacity is common and benign; obstruction has decreased in frequency, is rare without cGVHD, and is associated with mortality; nonsibling and mismatched donor are risk factors for restriction.
我们对1980年至1997年间接受异基因骨髓移植(BMT)的6个月存活者进行了一项回顾性队列研究,以评估其长期肺功能测试(PFT)情况。在593例患者中,分别有73%、71%和65%的患者有足够数据来评估阻塞性、限制性和弥散性损伤。在超过5年的时间里,1秒用力呼气容积/用力肺活量(FEV1/FVC)、肺总量(TLC)和弥散的平均下降率分别为4%、7%和17%。TLC和弥散随后有上升趋势。总体而言,分别有6%、12%和35%的患者符合阻塞性、限制性和弥散受损的标准。阻塞性病变在近期移植患者中较少见(5%对15%,P = 0.004),而限制性和弥散受损率保持稳定。阻塞性病变患者的死亡率显著更高(风险比[HR] 2.0[1.04 - 3.95]),限制性病变患者的死亡率有升高但无统计学意义(HR 1.6[0.95 - 2.75]),而弥散受损患者的死亡率无明显升高(HR = 0.99[0.65 - 1.50])。慢性移植物抗宿主病(cGVHD)(比值比[OR] 16.7[2.2 - 129.8])和白消安(OR 2.9[1.01 - 8.24])与阻塞性病变相关。来自非同胞或配型不合供者的骨髓(OR 4.9[2.2 - 10.7])与限制性病变相关。总之,BMT后,弥散能力下降常见且为良性;阻塞性病变的发生率有所下降,若无cGVHD则罕见,且与死亡率相关;非同胞和配型不合供者是限制性病变的危险因素。